Next Generation in Protein Characterization
Aggregation
Quantitation
Stability
Structure
Similarity
"RedShiftBio provides a next-generation infrared technology with advanced data analytics to facilitate better, faster decision making in biopharmaceutical development from discovery to market via the direct measurement of previously undetectable change in protein structural attributes critical to drug product efficacy and quality."
AQS3pro Microfluidic Modulation Spectrometer
The Next Generation in Protein Characterization
The AQS3pro brings protein secondary structure measurement into every stage of the biopharmaceutical pipeline. Measuring in conditions that were previously not possible with traditional methods, MMS provides repeatable, high sensitivity, automated measurement across a wide concentration range, in any formulation.
See change in your protein, in your workflow, and in your efficiency.
Latest News
RedShiftBio Appoints Julien Bradley as new CEO Read more
RedShiftBio Expands Team to Support Launch of FlagShip AQS3™pro System for Protein Characterization.
Instrument Business Outlook interviews RedShiftBio CCO Jeff Zonderman on the launch of the AQS3pro.
Spectroscopy Europe highlights the launch of the AQS3pro.
RedShiftBio Launches AQS3pro Protein Characterization System.
Higher Order Structure (HOS) 2020, Apr 20-22, Gaithersburg, MD - CANCELED
13th Annual Proteins & Antibodies Congress, Apr 27-29, London, UK - POSTPONED
PEGS, May 4-8, Boston, MA
ASMS, May 31 - June 4, Houston, TX
Well Characterized Biologics and Biological Assays, Oct 27-29, Hyattsville, MD
PEGS EU, Nov 2020, Lisbon, Portugal
RedShiftBio®
RedShiftBio® is an innovative provider of analytical instrumentation for the research, development and manufacturing of protein therapeutic drugs.
Awards
Contact Us
RedShift BioAnalytics Inc.
131 Middlesex Turnpike
Burlington, MA 01803
T: 781.345.7300
F: 781-345-7301
E: info@redshiftbio.com
RedShift™, RedShiftBio®, See Change®, and AQS3™ are trademarks of RedShift BioAnalytics, Inc.